Beta Drugs MD, chairman, board of directors and AGM
Share price at the NSE close on 23 Oct 2026. Previous close ₹1,971.00.
- Under NSE's long-term additional surveillance, stage I, on the list for 23 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹2,107 Cr1,305th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 22 Oct 2026
- 39.0
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 22 Oct 2026
- 4.8
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 22 Oct 2026
- 16.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 22 Oct 2026
- 14.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026. The filing of 22 Oct 2026
- 0.10
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 1,55,58635.7% delivered
Beta Drugs board of directors
At the end of the quarter to Sep 2026, as the company filed it; changes since are in its announcements.Their trades in its shares
- Chairperson and managing directorRAHUL BATRA
- Managing directorVARUN BATRA
- Company Secretary and Compliance OfficerRAJNI BRAR
10 directors5 independent4 executive1 non-executive
- RAHUL BATRA · Chairperson and managing directorExecutive · joined Aug 2014 · 1 listed board · 1 committee seat
- VARUN BATRA · Managing directorExecutive · joined Aug 2014 · 1 listed board
- BALWANT SINGHExecutive · joined Aug 2014 · 1 listed board
- ASHUTOSH SHUKLAExecutive · joined Jan 2022 · 1 listed board
- MANMOHAN KHANNAIndependent · joined Jul 2017 · reappointed Jul 2022 · 60 months as independent · 0 listed boards · 1 as independent · 1 committee seat, 1 as chair
- ROHIT PARTIIndependent · joined Jul 2017 · reappointed Jul 2022 · 60 months as independent · 0 listed boards · 1 as independent · 1 committee seat
- MONICA JAINIndependent · joined Feb 2025 · 60 months as independent · 0 listed boards · 1 as independent
- LALIT KUMAR WATTSIndependent · joined Feb 2025 · 60 months as independent · 0 listed boards · 1 as independent
- SANJAY SEHGALIndependent · joined Nov 2024 · 60 months as independent · 0 listed boards · 1 as independent
- AJAY MAHIPALNon-executive · joined Nov 2024 · 60 months as independent · 1 listed board
An independent director has no business or family tie to the company, its promoters or its managers beyond the seat. Listed boards counts the boards of listed companies the director sits on, this one included, and "as independent" how many of those seats are independent ones. Committee seats are audit and stakeholder committee seats across those companies. Months as independent is filed for independent directors only, whose terms the rules cap. Disqualified is the company's own mark that a director may not serve under company law.
Committees and meetings
Who sits on each, and how often they met.Board meeting notices and outcomes
Board
- 26 Sep 20268 of 10 present4 independent · 22 days in between
- 3 Sep 202610 of 10 present5 independent · 15 days in between
- 18 Aug 20269 of 10 present5 independent · 3 days in between
- 14 Aug 20269 of 10 present5 independent · 24 days in between
3 earlier meetings
- 20 Jul 20269 of 10 present5 independent · 12 days in between
- 7 Jul 20269 of 10 present5 independent · 42 days in between
- 25 May 202610 of 10 present5 independent
Audit Committee
Chair MANMOHAN KHANNA
RAHUL BATRA, ROHIT PARTI
- 3 Sep 20263 of 3 present2 independent · 19 days in between
- 14 Aug 20263 of 3 present2 independent · 24 days in between
- 20 Jul 20263 of 3 present2 independent
Nomination and remuneration committee
Chair MANMOHAN KHANNA
RAHUL BATRA, ROHIT PARTI, SANJAY SEHGAL
- 3 Sep 20263 of 4 present2 independent · 57 days in between
- 7 Jul 20264 of 4 present3 independent
Stakeholders Relationship Committee
Chair MANMOHAN KHANNA
RAHUL BATRA, ROHIT PARTI
- 3 Sep 20263 of 3 present2 independent
Corporate Social Responsibility Committee
Chair RAHUL BATRA
VARUN BATRA, ROHIT PARTI
No meeting listed in the filing.
Meetings in the quarter filed and the one before it. The days in between are as the company files them, neither meeting's day counted; the rules allow at most 120. A quorum is the least number of members who must attend for the meeting to decide anything.
Statutory auditor
Named in the results for the quarter to Sep 2025.
- KHURANA SHARMA & COMPANYPeer-review certificate valid to Feb 2027
A statutory auditor checks the company's accounts and signs its results. Peer review is the accountants' institute's check of an audit firm's own work, which a listed company's auditor must hold a valid certificate of.
Beta Drugs AGM and shareholder votes
Each resolution, how the votes went, and how institutions voted apart from the promoters. A postal ballot is a vote by post or online, held without a meeting.Beta Drugs share news and announcements
Annual general meeting, 30 Sep 2026
10,315 shareholders on the register on 23 Sep 2026; present: 5 promoters and 31 others; votes counted by DINESH BHANDARI / PROPRIETOR.The company's voting result (opens in a new tab)
Adoption of Financial Statements (I) Audited Standalone Financial Statements of the Company for the financial year ended on March 31, 2026 and the Reports of the Board of Directors and Auditors thereon; and (II) Audited Consolidated Financial Statements of the Company for the financial year ended on March 31, 2026, together with the Report of the Auditors thereonMoreLess
Ordinary100.00% for0.00% againstAgainst: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 100.00% · promoters 100.00% · institutions 100.00% · other public 100.00%
- To appoint a director in place of Mr. Ajay Mahipal (DIN: 06949940), who retires by rotation and being eligible for, offers himself for re-appointment.Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 100.00% · promoters 100.00% · institutions 100.00% · other public 100.00%
- To appoint a Director in place of Mr. Ashutosh Shukla (DIN: 09461568), who retires by rotation and being eligible, offers himself for re-appointment.Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 100.00% · promoters 100.00% · institutions 100.00% · other public 100.00%
- To re-appoint Statutory Auditors of the CompanyOrdinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 100.00% · promoters 100.00% · institutions 100.00% · other public 100.00%
To ratify the remuneration payable to the Cost Auditor appointed by the Board of Directors of the Company for the financial year 2026-27 pursuant to Section 148 and all other applicable provisions of Companies Act, 2013.MoreLess
Ordinary100.00% for0.00% againstAgainst: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 100.00% · promoters 100.00% · institutions 100.00% · other public 100.00%
- To re-appoint Mr. Ashutosh Shukla (DIN No. 09461568), Whole time Director of the company w.e.f 20th January 2027 to 19th January 2032 and to revise the remuneration payable to Mr. Ashutosh Shukla.Special100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 100.00% · promoters 100.00% · institutions 100.00% · other public 100.00%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
Extraordinary general meeting, 4 Feb 2026, 4 resolutions
4,024 shareholders on the register on 29 Jan 2026; present: 5 promoters and 11 others; votes counted by Dinesh Bhandari / Dinesh Bhandari.The company's voting result (opens in a new tab)
- Approval of increase in Authorised Share Capital of the Company and Consequent Alteration in The Capital Clause of The Memorandum of Association of the Company.Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 100.00% · promoters 100.00% · institutions 100.00% · other public 100.00%
- Approval of Beta Drugs Limited Employee Stock Option Plan 2026Special100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 100.00% · promoters 100.00% · institutions 100.00% · other public 100.00%
- Approval of Extending the Benefits of Beta Drugs Limited Employee Stock Option Plan 2026 to the Employees of the Group Companies including Holding, Subsidiary and Associate Companies of the Company.Special100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 100.00% · promoters 100.00% · institutions 100.00% · other public 100.00%
Approval of the Issue and Offer of 2,83,668 (Two Lakh Eighty-Three Thousand Six Hundred and Sixty-Eight) Equity Shares of the Company of Face Value of INR 10 Each, at a Price of INR 1712.49 (Indian Rupees One Thousand Seven Hundred Twelve and Forty-Nine Paisa) Per Equity Share Including a Premium of INR 1702.49 (Indian Rupees One Thousand Seven Hundred Two and Forty-Nine Paisa) Per Equity Share to the specified Persons.MoreLess
Special100.00% for0.00% againstAgainst: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 100.00% · promoters 100.00% · institutions 100.00% · other public 100.00%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
Annual general meeting, 30 Sep 2025, 7 resolutions
3,282 shareholders on the register on 23 Sep 2025; present: 5 promoters and 11 others; votes counted by DINESH BHANDARI / DINESH BHANDARI PRACTISING COMPANY SECRETARY.The company's voting result (opens in a new tab)
Adoption of Financial Statements (I) Audited Standalone Financial Statements of the Company for the financial year ended on March 31, 2025 and the Reports of the Board of Directors and Auditors thereon; and (II) Audited Consolidated Financial Statements of the Company for the financial year ended on March 31, 2025, together with the Report of the Auditors thereonMoreLess
Ordinary100.00% for0.00% againstAgainst: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 100.00% · promoters 100.00% · institutions 100.00% · other public 100.00%
- To appoint a Director in place of Mr. Rahul Batra (DIN: 02229234), who retires by rotation and being eligible, offers himself for reappointment.OrdinaryPromoters have an interest in it100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 100.00% · promoters 100.00% · institutions 100.00% · other public 100.00%
- To appoint a Director in place of Mr. Balwant Singh (DIN: 01089968), who retires by rotation and being eligible, offers himself for reappointment.Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 100.00% · promoters 100.00% · institutions 100.00% · other public 100.00%
To ratify the remuneration payable to the Cost Auditor appointed by the Board of Directors of the Company for the financial year 2025-26 pursuant to Section 148 and all other applicable provisions of Companies Act, 2013.MoreLess
Ordinary100.00% for0.00% againstAgainst: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 100.00% · promoters 100.00% · institutions 100.00% · other public 100.00%
- To appoint Secretarial Auditors of the CompanyOrdinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 100.00% · promoters 100.00% · institutions 100.00% · other public 100.00%
- Re-appointment of Mr. Rahul Batra (DIN: 02229234) as Chairman cum Managing Director of the Company w.e.f. 27th January, 2026 till 26th January, 2031.SpecialPromoters have an interest in it100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 100.00% · promoters 100.00% · institutions 100.00% · other public 100.00%
- Re-appointment of Mr. Varun Batra (DIN: 02148383) as Joint Managing Director of the Company w.e.f. 27th January, 2026 till 26th January, 2031.SpecialPromoters have an interest in it100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 100.00% · promoters 100.00% · institutions 100.00% · other public 100.00%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
Postal ballot, 11 Mar 2025, 5 resolutions
2,964 shareholders on the register on 31 Jan 2025; votes counted by DINESH BHANDARI / DINESH BHANDARI PRACTICING COMPANY SECRETARY.The company's voting result (opens in a new tab)
- TO APPROVE THE INCREASE IN AUTHORISED SHARE CAPITAL OF THE COMPANY AND CONSEQUENT ALTERATION IN THE CAPITAL CLAUSE OF THE MEMORANDUM OF ASSOCIATION OF THE COMPANY.Ordinary99.99% for0.01% against
Against: promoters 0.00% · institutions 0.00% · other public 2.91%
Turnout: all 67.80% · promoters 99.98% · institutions 62.69% · other public 0.78%
- ISSUE OF BONUS SHARESSpecial99.99% for0.01% against
Against: promoters 0.00% · institutions 0.00% · other public 2.91%
Turnout: all 67.80% · promoters 99.98% · institutions 62.69% · other public 0.78%
- APPOINTMENT OF MRS MONICA JAIN (DIN: 05253864) AS AN INDEPENDENT DIRECTOR OF THE COMPANYSpecial99.99% for0.01% against
Against: promoters 0.00% · institutions 0.00% · other public 2.91%
Turnout: all 67.80% · promoters 99.98% · institutions 62.69% · other public 0.78%
- APPOINTMENT OF MR LALIT KUMAR WATTS (DIN:10906518) AS AN INDEPENDENT DIRECTOR OF THE COMPANYSpecial99.99% for0.01% against
Against: promoters 0.00% · institutions 0.00% · other public 2.91%
Turnout: all 67.80% · promoters 99.98% · institutions 62.69% · other public 0.78%
MIGRATION OF LISTING / TRADING OF EQUITY SHARES OF THE COMPANY FROM EMERGE PLATFORM OF NATIONAL STOCK EXCHANGE OF INDIA LIMITED TO MAIN BOARD OF NATIONAL STOCK EXCHANGE OF INDIA LIMITED (“NSE”) AS WELL AS ON MAIN BOARD OF BSE LIMITED (“BSE”):MoreLess
Special99.99% for0.01% againstAgainst: promoters 0.00% · institutions 0.00% · other public 2.91%
Turnout: all 67.80% · promoters 99.98% · institutions 62.69% · other public 0.78%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
Extraordinary general meeting, 21 Dec 2024, 3 resolutions
Present: 5 promoters and 11 others.The company's voting result (opens in a new tab)
- ADOPTION OF THE RESTATED ARTICLES OF ASSOCIATION OF THE COMPANY.Special100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 100.00% · promoters 100.00% · institutions 0.00% · other public 100.00%
- APPOINTMENT OF MR. SANJAY SEHGAL, (DIN: 01235531) AS INDEPENDENT DIRECTOR OF THE COMPANY.Special100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 100.00% · promoters 100.00% · institutions 0.00% · other public 100.00%
- APPOINTMENT OF MR. AJAY MAHIPAL (DIN: 06949940) AS A DIRECTOR OF THE COMPANY.Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 100.00% · promoters 100.00% · institutions 0.00% · other public 100.00%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
Extraordinary general meeting, 12 Nov 2024, 3 resolutions
Present: 5 promoters and 11 others.The company's voting result (opens in a new tab)
- 1. TO APPROVE THE INCREASE IN AUTHORISED SHARE CAPITAL OF THE COMPANY AND CONSEQUENT ALTERATION IN THE CAPITAL CLAUSE OF THE MEMORANDUM OF ASSOCIATION OF THE COMPANY. nnOrdinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 100.00% · promoters 100.00% · institutions 0.00% · other public 100.00%
- ISSUANCE OF EQUITY SHARES AND COMPULSORY CONVERTIBLE DEBENTURES OF THE COMPANY ON PREFERENTIAL BASISSpecial100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 100.00% · promoters 100.00% · institutions 0.00% · other public 100.00%
- APPROVAL OF SPECIAL RIGHTS PROPOSED TO BE GRANTED TO HEALTHQUAD FUND II (A FUND UNDER HEALTHQUAD TRUST II) AND Inti Capital VCC - Inti Capital ISpecial100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 100.00% · promoters 100.00% · institutions 0.00% · other public 100.00%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
Annual general meeting, 30 Sep 2024, 11 resolutions
Present: 5 promoters and 11 others.The company's voting result (opens in a new tab)
1. Adoption of Financial Statementsnn(I) Audited Standalone Financial Statements of the Company for the financial year ended on March 31, 2024 and the Reports of the Board of Directors and Auditors thereon;n andn (II) Audited Consolidated Financial Statements of the Company for the financial year ended on March 31, 2024, together with the Report of the Auditors thereonnMoreLess
Ordinary100.00% for0.00% againstAgainst: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 100.00% · promoters 100.00% · institutions 0.00% · other public 100.00%
- To appoint a Director in place of Mr. Varun Batra (DIN: 02148383), who retires by rotation and being eligible, offers himself for re-appointment.OrdinaryPromoters have an interest in it100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 100.00% · promoters 100.00% · institutions 0.00% · other public 100.00%
- To appoint a Director in place of Mrs. Seema Chopra (DIN: 08510586), who retires by rotation and being eligible, offers herself for re-appointment.Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 100.00% · promoters 100.00% · institutions 0.00% · other public 100.00%
- To appoint Statutory Auditors from the conclusion of this Annual General Meeting until the conclusion of the Twenty first Annual General Meeting and to fix their remuneration.Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 100.00% · promoters 100.00% · institutions 0.00% · other public 100.00%
To ratify the remuneration payable to the Cost Auditor appointed by the Board of Directors of the Company for the financial year 2024-25 pursuant to Section 148 and all other applicable provisions of Companies Act, 2013.MoreLess
Ordinary100.00% for0.00% againstAgainst: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 100.00% · promoters 100.00% · institutions 0.00% · other public 100.00%
- To revise the remuneration payable to Mr. Rahul Batra (DIN No. 02229234), Managing Director of the company.SpecialPromoters have an interest in it100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 100.00% · promoters 100.00% · institutions 0.00% · other public 100.00%
- To revise the remuneration payable to Mr. Varun Batra (DIN No. 02148383), Joint Managing Director of the company.SpecialPromoters have an interest in it100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 100.00% · promoters 100.00% · institutions 0.00% · other public 100.00%
- Re-appointment of Mr. Balwant Singh (DIN: 01089968) as Whole-time Director of the Company w.e.f. 5th August, 2024 till 4th August, 2029.Special100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 100.00% · promoters 100.00% · institutions 0.00% · other public 100.00%
- Re-appointment of Mrs. Seema Chopra (DIN: 08510586) as Whole-time Director of the Company w.e.f. 1st August, 2024 till 31st July, 2029.Special100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 100.00% · promoters 100.00% · institutions 0.00% · other public 100.00%
- To revise the remuneration payable to Mr. Ashutosh Shukla (DIN No. 09461568), Whole time Director of the company.Special100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 100.00% · promoters 100.00% · institutions 0.00% · other public 100.00%
- To alter the incidental object of the Memorandum of Association of the companySpecial100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 100.00% · promoters 100.00% · institutions 0.00% · other public 100.00%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
Extraordinary general meeting, 28 Jun 2019, 2 resolutions
Present: 4 promoters and 3 others.The company's voting result (opens in a new tab)
- APPROVAL OF RELATED PARTY TRANSACTIONUNDER SECTION 188 OF COMPANIES ACT, 2013OrdinaryPromoters have an interest in it100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 100.00% · promoters 0.00% · institutions 0.00% · other public 100.00%
- TO CONSIDER AND APPROVE ISSUE OF 3,19,046 EQUITY SHARES ON PREFERENTIAL BASISSpecialPromoters have an interest in it100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 100.00% · promoters 0.00% · institutions 0.00% · other public 100.00%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
Investor complaints and compliance
Quarter by quarter.
Investor complaints received and resolved, the company's own count
- Received
- Resolved
Open at the quarter's end
- The board is made up as the listing rules require
- Yes
- The board has a regular chairperson
- Yes
- The company has a risk management committee
- No
- The chair is related to the managing director
- Yes
- The filing has a part on fines and penalties
- No
- The filing has a part on tax disputes
- No
- There was a cyber security incident in the quarter
- No
The company's own answers in its filing.
How money raised was used
Reported for the quarter to Sep 2026. A preferential issue sells new shares to chosen investors rather than to the public. A warrant or partly paid issue plans the whole issue while the money comes in over time, so the amount set aside can be more than raised so far. A statement's amounts are left out where the raise it states and its own uses differ by fifty times or more, a figure typed at the wrong scale.
| Raised | Amount raised | For | Set aside | Spent | Spent elsewhere |
|---|---|---|---|---|---|
| Preferential IssuesNov 2024, checked by Brickwork Ratings India Private Limited | – | Facility Upgradation of 100% Subsidiary - Adley Formualtions Pvt Ltd. | – | – | No |
| Preferential IssuesNov 2024, checked by Brickwork Ratings India Private Limited | – | Facility Upgradation of 100% Subsidiary - Adley Lab Ltd. | – | – | No |
| Preferential IssuesNov 2024, checked by Brickwork Ratings India Private Limited | – | R & D facilty (new setup) | – | – | No |
| Preferential IssuesNov 2024, checked by Brickwork Ratings India Private Limited | – | Geographical Expansion it includes new registrations, audits, dossiers costs, bioequivalence studies cost. | – | – | No |
| Preferential IssuesNov 2024, checked by Brickwork Ratings India Private Limited | – | Capital Expenditure (Manufacturing- new setup) | – | – | No |
| Preferential IssuesNov 2024, checked by Brickwork Ratings India Private Limited | – | Capital Investment (including capital acquisitions) | – | – | No |
| Preferential IssuesNov 2024, checked by Brickwork Ratings India Private Limited | – | General Corporate Purpose | – | – | No |